Therapy Directory

Bortezomib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Bortezomib as a study intervention. Browse Bortezomib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Aug 17, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Local indexed summaries

Local recruiting

The trial list below is retrieved from the live ClinicalTrials.gov search API for Bortezomib. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 87 matching trials for Bortezomib.

Indexed local directory records.

Top conditions

Multiple Myeloma 42 Plasma Cell Myeloma 6 AL Amyloidosis 4 Newly Diagnosed Multiple Myeloma 4 Acute Myeloid Leukemia 3 Acute Lymphoblastic Leukemia 2

Top sponsors

Janssen Research & Development, LLC 10 National Cancer Institute (NCI) 6 GlaxoSmithKline 5 M.D. Anderson Cancer Center 5 Celgene 4 Dana-Farber Cancer Institute 3

Top locations

New York, New York 38 Boston, Massachusetts 37 Houston, Texas 28 Detroit, Michigan 27 Seattle, Washington 25 Atlanta, Georgia 23

Indexed official records

Open in full search

Conditions: Multiple Myeloma
Interventions: Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib, Dexamethasone, Lenalidomide; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years to 79 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: La Crosse, Wisconsin

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: AZD0120, Bortezomib, Cyclophosphamide, Daratumumab, Dexamethasone, Fludarabine, Isatuximab, Lenalidomide; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 45
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Amyloidosis
Interventions: Belantamab mafodotin, Bortezomib, Cyclophosphamide, Dexamethasone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: Bortezomib, Daratumumab, Dexamethasone, Elranatamab, Lenalidomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 10
States / cities: Jupiter, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: Graft-versus-host Disease
Interventions: Abatacept, Bortezomib, Cyclophosphamide; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 14 Years to 100 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, Bortezomib, Carfilzomib, Dexamethasone, Pomalidomide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Torrance, California • Fort Myers, Florida • Macon, Georgia + 3 more

Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 1,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 642
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 457 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Etentamig, Pomalidomide, Selinexor; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Elranatamab, Pomalidomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 97
States / cities: Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more

Conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions: Bortezomib, Carfilzomib, Daratumumab, Dexamethasone, Linvoseltamab, Pomalidomide; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 2
States / cities: New York, New York • Columbus, Ohio

Conditions: Multiple Myeloma
Interventions: Anitocabtagene Autoleucel, Bortezomib, Carfilzomib, Cyclophosphamide, Daratumumab, Dexamethasone, Fludarabine, Pomalidomide; Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 50
States / cities: Gilbert, Arizona • Duarte, California • Los Angeles, California + 37 more

Conditions: AL Amyloidosis
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration; Procedure · Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 117
States / cities: Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more

About this Bortezomib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Bortezomib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bortezomib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Bortezomib clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Indexed official records

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

About this Bortezomib clinical trials directory page